📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
202 analysed today
FollowTelegram
202
Today
152,064
All-time analysed
43,616
Positive
6,746
Negative
92,855
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
SBI Life Declares Interim Dividend of ₹2.70 Per Share for FY 2025-26
SBI Life Insurance has declared an interim dividend of ₹2.70 per equity share for the financial year 2025-26, which represents 27% of the face value. The company has established March 06, 2026, as the record date for determining shareholder eligibility, with the payout scheduled to be completed by March 27, 2026. Furthermore, the board is seeking shareholder approval via postal ballot for material related party transactions with State Bank of India and other group entities for the upcoming fiscal year 2026-27. This announcement underscores the company's consistent dividend policy and proactive regulatory planning for its bancassurance operations.
Key Highlights
Interim dividend of ₹2.70 per equity share declared for FY 2025-26
Record date for dividend entitlement is fixed as March 06, 2026
Dividend payment to be processed on or before March 27, 2026
Shareholder approval sought for material related party transactions with SBI and affiliates for FY 2026-27
Postal ballot e-voting period scheduled from March 01 to March 30, 2026
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of March 06, 2026. The related party transactions are standard for SBI Life's business model and are unlikely to impact the stock's fundamental valuation.
SBI Life Declares Interim Dividend of ₹2.70 per Share for FY 2025-26
SBI Life Insurance Company has declared an interim dividend of ₹2.70 per equity share for the financial year 2025-26, representing a 27% payout on the face value of ₹10. The company has fixed March 06, 2026, as the record date for determining shareholder eligibility, with the payment scheduled to be completed by March 27, 2026. Furthermore, the board has initiated a postal ballot to seek approval for material related party transactions for FY 2026-27. These transactions involve major entities including State Bank of India and Yes Bank, which are critical to the company's bancassurance distribution model.
Key Highlights
Interim dividend of ₹2.70 per equity share (27% of face value) declared for FY 2025-26
Record date for dividend eligibility set for March 06, 2026
Dividend payout to shareholders to be completed on or before March 27, 2026
Shareholder approval sought for Material Related Party Transactions with SBI and Yes Bank for FY 2026-27
Postal ballot e-voting period scheduled from March 01 to March 30, 2026
👀 What to Watch
Investors looking to benefit from the dividend should ensure they hold the stock before the ex-dividend date associated with the March 06 record date. The related party transaction approvals are routine for the company's business model and should be viewed as standard regulatory compliance.
Biocon to Consolidate 100% of Biologics Unit; Net Debt/EBITDA Drops to 2.8x
Biocon is integrating its Generics and Biosimilars businesses to simplify its corporate structure and remove the holding company discount. The company has successfully reduced its Net Debt/EBITDA from 4.3x to 2.8x following a ₹4,500 crore QIP and strategic refinancing of $1.2 billion. This deleveraging is expected to result in annual interest savings of approximately ₹300 crore. With major CapEx cycles largely completed, the company is now focusing on a pipeline of 30+ biosimilars and 3 GLP-1 products targeting a $200 billion market opportunity.
Key Highlights
Raised ₹4,500 crore via QIP to redeem structured debt, saving ₹300 crore in annual interest costs.
Net Debt/EBITDA leverage improved significantly from 4.3x in FY23 to 2.8x in 9MFY26.
Board approved acquiring the remaining ~2% stake in Biocon Biologics to achieve 100% ownership.
Refinanced $1.2 billion in debt, including an $800 million bond, extending maturity by 5 years.
Future growth driven by 30+ biosimilars and 3 GLP-1s addressing a $200B+ market opportunity.
👀 What to Watch
Investors should favor the improved balance sheet and simplified structure which addresses previous concerns regarding high debt and complex subsidiary holdings. Monitor the commercial progress of the GLP-1 pipeline as a key catalyst for future valuation rerating.
Biocon Obtains US FDA Approval for Liraglutide (gSaxenda) Weight Management Drug
Biocon has received US FDA approval for its generic version of Saxenda (Liraglutide), a drug-device combination for chronic weight management. This approval marks a significant entry into the high-growth GLP-1 therapy market in the United States, which had an addressable market of $127 million as of December 2025. The product is a 18 mg/3 mL prefilled pen, validating Biocon's vertically integrated manufacturing capabilities. This development is expected to be a key revenue driver for Biocon's US generics business in the coming years.
Key Highlights
Received US FDA approval for Liraglutide Injection 18 mg/3 mL (6 mg/mL) prefilled pens.
Targets the US GLP-1 weight loss market, valued at approximately $127 million in 2025.
First-of-its-kind drug-device combination approval for Biocon in the GLP-1 category.
Strengthens Biocon's position in one of the fastest-growing therapeutic classes globally.
👀 What to Watch
Investors should view this as a major positive catalyst for Biocon's US portfolio expansion. Monitor the commercial launch timeline and market share capture in the competitive GLP-1 segment.
Triveni Turbine Seeks Re-appointment of Nikhil Sawhney as MD for 5-Year Term
Triveni Turbine Limited has issued a postal ballot notice to seek shareholder approval for the re-appointment of Mr. Nikhil Sawhney as Managing Director, designated as Vice Chairman and Managing Director. The proposed tenure is for a period of five years, effective from May 10, 2026. The voting process will be conducted via remote e-voting, starting from February 25, 2026, and concluding on March 26, 2026. This move is intended to ensure leadership stability and continuity in the company's strategic management.
Key Highlights
Proposed re-appointment of Mr. Nikhil Sawhney as Managing Director for a 5-year term starting May 10, 2026
Remote e-voting period set from February 25, 2026, 9:00 A.M. to March 26, 2026, 5:00 P.M.
Cut-off date for eligibility to vote is February 20, 2026
Results of the postal ballot to be declared on or before March 30, 2026
The resolution is proposed as a Special Resolution requiring requisite majority approval
👀 What to Watch
Investors should monitor the voting results to confirm leadership continuity, which is generally positive for long-term stability. No immediate action is required other than participating in the e-voting process if desired.
MobiKwik Receives BSE Approval to Launch Stock Broking Business Effective Feb 24, 2026
One MobiKwik Systems' subsidiary, MSBPL, has received final approval from the BSE to commence stock broking operations starting February 24, 2026. This follows the SEBI registration obtained in July 2025, allowing the company to offer equity trading, clearing, and settlement services. With a massive user base of over 186.6 million registered users, MobiKwik is well-positioned to cross-sell broking services to its existing digital wallet and payment customers. This move marks a significant step in the company's transition into a comprehensive financial services provider.
Key Highlights
BSE approval received for stock broking; operations to commence from February 24, 2026.
Follows SEBI registration granted in July 2025, completing regulatory requirements for the subsidiary MSBPL.
MobiKwik currently serves over 186.6 million registered users and 4.79 million merchants.
Company holds an 18% market share in the PPI wallet gross transaction value as of December 2025.
👀 What to Watch
Investors should monitor the adoption rate of the broking platform among MobiKwik's existing 186 million users as it competes with established discount brokers. Successful scaling of this business could significantly enhance the company's average revenue per user (ARPU).
MobiKwik Subsidiary Receives BSE Approval to Commence Business as Trading Member
One MobiKwik Systems Limited's wholly-owned subsidiary, MobiKwik Securities Broking Private Limited, has received formal approval to commence business as a trading member on the BSE. This milestone follows the subsidiary's incorporation in March 2025 and its SEBI registration as a stock broker in July 2025. The approval allows MobiKwik to officially enter the stock broking market, diversifying its fintech ecosystem. This move is expected to enhance the company's revenue streams by leveraging its existing user base for investment services.
Key Highlights
MobiKwik Securities Broking Private Limited received BSE approval for business commencement on February 23, 2026.
The subsidiary is a 100% wholly-owned entity of One MobiKwik Systems Limited.
Follows the SEBI Certificate of Registration as a stock broker received on July 03, 2025.
The subsidiary was originally incorporated on March 26, 2025, to facilitate entry into the broking segment.
Approval was officially recorded by the company at 17:34 P.M. on the date of notification.
👀 What to Watch
Investors should view this as a positive step toward business diversification and monitor the company's ability to scale its broking operations against established competitors. Watch for upcoming user acquisition costs and the impact on overall fintech margins.
SBI Life to Consider Interim Dividend on Feb 25; Record Date Set for March 06, 2026
SBI Life Insurance Company has scheduled a board meeting on February 25, 2026, to deliberate on the declaration of an interim dividend for the financial year 2025-26. The company has proactively fixed March 06, 2026, as the record date to identify eligible shareholders for the potential payout. In compliance with insider trading regulations, the trading window for designated persons is closed from February 21 to February 27, 2026. This move indicates the company's intent to distribute surplus cash to its shareholders.
Key Highlights
Board meeting scheduled for February 25, 2026, to consider interim dividend for FY 2025-26
Record date for dividend eligibility fixed as March 06, 2026
Trading window for insiders closed from February 21 to February 27, 2026
The dividend amount will be determined during the upcoming board meeting
👀 What to Watch
Investors should watch for the dividend amount announcement on February 25 and ensure they hold shares before the ex-dividend date to qualify for the payout.
SBI Life Board to Consider Interim Dividend on Feb 25; Record Date Set for March 06
SBI Life Insurance Company Limited has scheduled a Board of Directors meeting on February 25, 2026, to consider and declare an interim dividend for the financial year 2025-26. The company has fixed March 06, 2026, as the record date for determining shareholder eligibility for the payout. In line with SEBI regulations, the trading window for designated persons is closed from February 21 to February 27, 2026. This announcement indicates a potential cash return to shareholders, pending board approval.
Key Highlights
Board meeting scheduled for February 25, 2026, to consider interim dividend for FY 2025-26.
Record date for determining dividend eligibility is fixed as March 06, 2026.
Trading window for insiders closed from February 21, 2026, to February 27, 2026.
The dividend declaration is subject to approval by the Board of Directors during the upcoming meeting.
👀 What to Watch
Investors should watch for the dividend amount announcement on February 25 and ensure they hold the stock before the March 06 record date to be eligible for the payout.
India Ratings Affirms BIL's Rating at IND BBB/Stable; Removes Negative Watch
India Ratings and Research (Ind-Ra) has affirmed the credit ratings for Bhartiya International Limited's bank loan facilities totaling INR 6,470.70 million. The agency assigned a long-term rating of 'IND BBB' with a Stable outlook and a short-term rating of 'IND A2'. Most significantly, the rating agency has removed the company from 'Rating Watch with Negative Implications' (RWN). This indicates a stabilization in the company's credit profile and a reduction in immediate financial risk factors.
Key Highlights
Total bank loan facilities rated amount to INR 6,470.70 million.
Long-term rating affirmed at 'IND BBB' with a 'Stable' outlook.
Short-term rating affirmed at 'IND A2'.
Successfully removed from 'Rating Watch with Negative Implications' (RWN), signaling improved credit stability.
👀 What to Watch
The removal of the negative watch is a positive signal for stakeholders, suggesting that the company's liquidity or operational concerns have stabilized. Investors should continue to monitor the company's debt levels and interest coverage ratios in upcoming quarterly reports.
SBI Life Receives Partial Relief in GST Case; Demand Reduced to ₹159.45 Crore
SBI Life Insurance has received an updated order from the GST appellate authority for FY 2018-19, providing partial relief. The total demand, which was previously ₹288.67 crore, has been reduced to ₹159.45 crore. This revised amount includes ₹63.36 crore in tax, ₹89.75 crore in interest, and ₹6.34 crore in penalty. The company has stated it will continue to contest the remaining demand by filing an appeal with the Appellate Tribunal.
Key Highlights
Total tax demand for FY 2018-19 reduced by approximately 45% to ₹159.45 crore
The original demand of ₹288.67 crore was first disclosed in April 2024
Key issues cited include ITC mismatches and non-reversal of credit on security transactions
SBI Life intends to file a further appeal against the partial demand upheld by the authority
👀 What to Watch
Monitor the progress of the appeal in the Appellate Tribunal; while the reduction is positive, the remaining liability is still noteworthy.
ABINFRA Q3 PAT Rises 16% YoY to ₹6.12 Cr; 9M Profit Surges 42%
A B Infrabuild Limited reported a steady performance for Q3 FY26, with Net Profit increasing by 16% YoY to ₹6.12 crore despite relatively flat revenue growth in the quarter. For the nine-month period ending December 2025, the company showed strong momentum, with revenue growing 26% to ₹172.27 crore and PAT surging 42% to ₹13.37 crore. The company successfully executed a 10:1 stock split in October 2025, which is reflected in the adjusted EPS. Operational efficiency appears to have improved as profit margins expanded significantly over the nine-month period.
Key Highlights
Net Profit for Q3 FY26 grew 16% YoY to ₹6.12 crore from ₹5.27 crore in Q3 FY25.
9M FY26 Revenue increased by 26.3% YoY to ₹172.27 crore compared to ₹136.42 crore in 9M FY25.
9M FY26 PAT jumped 42.4% YoY to ₹13.37 crore against ₹9.39 crore in the previous year period.
Earnings Per Share (EPS) for the nine-month period stood at ₹0.21 on a post-split basis (Face Value ₹1).
Profit Before Tax (PBT) for 9M FY26 reached ₹18.08 crore, up from ₹12.79 crore in 9M FY25.
👀 What to Watch
The company demonstrates strong bottom-line growth and margin expansion, particularly over the 9-month horizon. Investors should monitor the sustainability of these margins and the company's ability to scale revenue in the upcoming final quarter of the fiscal year.
Concord Biotech Q3 FY26 Revenue Grows 14% to ₹278 Cr; API Segment Surges 24%
Concord Biotech reported a recovery in Q3 FY26 with revenue growing 14% YoY to ₹278 crores, though 9-month revenue remains 5% lower at ₹729 crores due to H1 disruptions. The API business was a major driver this quarter, growing 24% to ₹219 crores, while the formulation segment saw a decline. Reported EBITDA margins stood at 35.6%, impacted by start-up costs for the new injectable facility; however, core margins remain healthy at 40%. Management expects a return to historical growth levels in FY27 as regulatory hurdles clear and the injectable business scales toward its ₹600 crore peak potential.
Key Highlights
Q3 FY26 revenue increased 14% YoY to ₹278 crores, led by strong API performance of ₹219 crores.
Adjusted EBITDA margins (excluding start-up and US subsidiary costs) remained stable at 40%.
The new injectable facility received WHO GMP certification, targeting a peak revenue of ₹600 crores.
9-month PAT stood at ₹64 crores, impacted by ₹3 crores in new labor code provisions and lower other income.
Company remains debt-free with cash and bank balances of ₹350 crores as of December 31, 2025.
👀 What to Watch
Investors should focus on the scale-up of the injectable facility and the resumption of Middle East tenders as primary growth drivers for FY27. The stock is a recovery candidate as temporary headwinds from H1 FY26, such as CDSCO delays and tariff uncertainties, have largely been resolved.
BILVYAPAR Schedules 5th Committee of Creditors Meeting Under Insolvency Process
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 5th meeting of its Committee of Creditors (CoC). The company is currently undergoing a Corporate Insolvency Resolution Process (CIRP) following an NCLT order dated January 13, 2026. The affairs, business, and assets of the company are being managed by the Resolution Professional, Ms. Rachna Jhunjhunwala. This meeting is a critical step in the insolvency proceedings to determine the future of the company's debt and operations.
Key Highlights
5th meeting of the Committee of Creditors (CoC) convened for BIL Vyapar Limited.
Company is under Corporate Insolvency Resolution Process (CIRP) as per NCLT order dated January 13, 2026.
Resolution Professional Ms. Rachna Jhunjhunwala is currently managing all company assets and affairs.
Disclosure made in compliance with Regulation 30 and Para 16(g) of SEBI LODR Regulations.
The company was formerly known as Binani Industries Limited before its name change.
👀 What to Watch
Investors should be extremely cautious as equity value is typically significantly impaired or wiped out during insolvency proceedings. Monitor upcoming disclosures regarding any submitted resolution plans or potential liquidation.
BirlaNu Limited (Formerly HIL) Unveils Q3 FY26 Investor Presentation with $1 Billion Vision
BirlaNu Limited, formerly HIL Limited, released its Q3 and 9M FY26 investor presentation detailing its strategic transformation and global footprint. The company operates 33 manufacturing facilities across India, Germany, and Austria, supported by a massive distribution network of 30,000+ retail points. With a vision to reach $1 billion in revenue, the company is diversifying across Pipes, Construction Chemicals, Putty, Roofs, Walls, and Floors. Digital engagement has seen a significant surge with 68 million interactions recorded in the first nine months of the fiscal year.
Key Highlights
Maintains a global manufacturing presence with 33 units and a distribution network of 30,000+ retail points and 21,000+ channel partners.
Installed capacities include 1.1 million MT for Roofs, 100k+ MTPA for Pipes, and 250k+ MTPA for Putty.
Digital transformation efforts resulted in over 68 million views and interactions across platforms during 9M FY26.
The company is part of the US$ 3 billion CKA Birla Group with a legacy of over 165 years.
Strategic focus remains on the 'Vision $1 billion' goal through innovation, sustainability, and technology-led growth.
👀 What to Watch
Investors should track the company's transition from HIL to the BirlaNu brand and its impact on market share in the competitive building materials segment. Monitor the execution of the $1 billion revenue roadmap and the performance of the newly acquired Clean Coats business.
Emmbi Industries Q3 FY26 PAT Drops 34% YoY to ₹11.17 Mn Impacted by Exceptional Item
Emmbi Industries reported a 9.1% YoY growth in consolidated net sales for Q3 FY26, reaching ₹1,122.37 million. However, net profit (PAT) declined significantly by 34.3% YoY to ₹11.17 million, largely due to a one-time exceptional expense of ₹11.71 million for Labour Code compliance. On a sequential basis, revenue and profit both saw a decline compared to Q2 FY26. Despite the quarterly dip, the nine-month performance remains positive with PAT up 14.7% compared to the previous year.
Key Highlights
Consolidated Net Sales grew 9.1% YoY to ₹1,122.37 million in Q3 FY26.
Net Profit (PAT) fell 34.3% YoY to ₹11.17 million from ₹17.00 million in the previous year.
A one-time exceptional provision of ₹11.71 million was recognized for compliance with new Labour Codes.
9-Month FY26 Consolidated PAT stands at ₹54.61 million, a 14.7% growth over 9M FY25.
Consolidated EPS for the quarter decreased to ₹0.58 from ₹0.94 in the year-ago period.
👀 What to Watch
The quarterly results are weak on the bottom line due to a one-time provision, though revenue growth remains stable YoY. Investors should watch for margin recovery in the next quarter to ensure operational costs are under control.
Tasty Bite Q3 FY26 PAT Surges 51% YoY; EBITDA Margins Expand to 18%
Tasty Bite Eatables reported a strong performance for the nine months ended December 2025, with PAT rising 51% YoY to ₹293 million. While YTD revenue growth was modest at 3%, the company saw a significant sequential revenue jump of 33% in Q3 FY26. Profitability improved sharply as EBITDA margins reached 18% in Q3, driven by operational efficiencies and a 128% growth in the Mars Affiliate business. Despite macroeconomic headwinds in the US consumer segment, the Food Service business maintained steady growth for the 9th consecutive quarter.
Key Highlights
YTD PAT increased by 51% YoY to ₹293 million, aided by lower interest costs and higher EBITDA.
Q3 FY26 EBITDA margin expanded to 18.0% from 10.4% in the preceding quarter.
Mars Affiliate Business grew by 128% YTD, offsetting a 9% decline in other affiliate segments.
Food Service Business (TFS) grew 16% YTD to ₹1,523 million, marking 9 consecutive quarters of growth.
Company is pivoting towards Indian retail growth via Amazon and upcoming quick-commerce expansions.
👀 What to Watch
Investors should focus on the significant margin expansion and the company's ability to offset US market weakness through the Mars partnership. The successful scaling of the India retail and quick-commerce strategy will be the key catalyst for future valuation re-rating.
Tasty Bite Q3 PAT Drops 10.6% YoY to ₹84.3M; New Chairman Appointed
Tasty Bite Eatables reported a 4.8% YoY increase in revenue from operations to ₹1,340.54 million for the quarter ended December 31, 2025. However, Net Profit (PAT) declined by 10.6% YoY to ₹84.30 million, primarily due to higher operating expenses and a one-time exceptional charge. For the nine-month period, PAT also saw a decline to ₹283.47 million compared to ₹319.08 million in the previous year. The company also announced a significant leadership change, with Rahul Bhatnagar set to succeed Pradeep Poddar as Chairman in April 2026.
Key Highlights
Revenue from operations grew 4.8% YoY to ₹1,340.54 million in Q3 FY26.
Net Profit for the quarter fell to ₹84.30 million from ₹94.34 million in the same period last year.
Recognized an exceptional item of ₹4.53 million as a provision for the New Labour Codes.
9M FY26 PAT stands at ₹283.47 million, down from ₹319.08 million in 9M FY25.
Chairman Pradeep Poddar to resign effective March 31, 2026; Rahul Bhatnagar appointed as successor.
👀 What to Watch
Investors should be cautious as the company is facing margin pressure despite stable revenue growth. Monitor the leadership transition and the impact of the New Labour Codes on future operating costs.
Gufic Bio Q3 Net Profit Declines 35% YoY to ₹12.4 Cr; Revenue Up 11% YoY
Gufic Biosciences reported a consolidated revenue of ₹231.4 crore for Q3 FY26, marking an 11.3% growth compared to the same quarter last year. However, net profit for the quarter fell sharply by 35.6% YoY to ₹12.4 crore, down from ₹19.3 crore in Q3 FY25. The profitability was primarily impacted by a significant rise in finance costs, which nearly doubled for the nine-month period to ₹27.2 crore. Additionally, the company announced a small strategic investment of up to USD 50,000 in Selvax Pty Ltd to acquire 3,78,350 ordinary shares.
Key Highlights
Consolidated Revenue for Q3 FY26 stood at ₹231.4 crore, up 11.3% YoY but down 2.4% QoQ.
Consolidated Net Profit for the quarter was ₹12.4 crore, a 35.6% decline from ₹19.3 crore in Q3 FY25.
Finance costs for the nine-month period ended Dec 2025 surged to ₹27.2 crore from ₹14.7 crore YoY.
9M FY26 Basic EPS dropped to ₹4.22 compared to ₹6.18 in 9M FY25.
Board approved further investment in Selvax Pty Ltd at AUD 20 cents per share, totaling up to USD 50,000.
👀 What to Watch
Investors should exercise caution as the company is facing significant margin pressure from rising interest and depreciation costs despite steady revenue growth. It is important to monitor the company's debt-servicing capability and the performance of its international subsidiaries.
Gufic Biosciences Targets 30% Indore Plant Utilization and EBITDA Breakeven in FY26
Gufic Biosciences has operationalized its advanced Indore facility as of October 2024, which features a monthly capacity of 5 million lyophilized vials and 6 million liquid vials. The company has already secured 203 product approvals for this facility and completed tech transfers for 40 products. Management expects the Indore unit to achieve EBITDA breakeven in FY26 at 30% utilization and become margin accretive by FY27. The strategic focus remains on high-growth platforms including Critical Care, Women's Health (IVF), and Botulinum Toxin (Aesthetics).
Key Highlights
Indore facility monthly capacity includes 5 million lyophilized vials, 6 million liquid vials, and 10 million ampoules.
Targeting 30% capacity utilization and EBITDA breakeven for the Indore facility during FY26.
Received 203 product approvals from State FDA for the Indore unit with more in the pipeline.
EU GMP and UK MHRA regulatory clearances for the new facility are targeted for Q1-FY27.
Strong growth in specialized brands like Guficin Alpha in the Reproductive Immunology segment.
👀 What to Watch
Investors should track the quarterly utilization rates of the Indore facility and the progress of EU GMP/UK MHRA audits in early FY27 as these are key catalysts for export growth. The company's transition from a pure-play manufacturer to a specialized platform provider in aesthetics and IVF offers potential for long-term margin expansion.
